![Jeremy Gowler](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jeremy Gowler
Direttore/Membro del Consiglio presso Versatope Therapeutics, Inc.
Patrimonio netto: - $ in data 31/05/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Christopher Locher | M | - |
Versatope Therapeutics, Inc.
![]() Versatope Therapeutics, Inc. BiotechnologyHealth Technology Versatope Therapeutics, Inc. is an immuno-therapeutic company based in Lowell, MA. The private company harnesses a customized biotechnology platform to deliver immunity using state-of-the-art synthetic biology and bioinformatics. The company customizes exosome-like vesicles made from probiotics to display targets in a 3D context that activates potent immunity. The company's lead vaccine candidate addresses the need for improved, effective universal influenza vaccines to prevent influenza and other emerging infectious diseases, such as the current COVID-19. The company was founded in 2017 by Christopher Locher and Dave Putnam, and Christopher Locher has been the CEO since 2017. | - |
William Duke | M | 51 | 1 anni | |
Dave Putnam | M | - |
Versatope Therapeutics, Inc.
![]() Versatope Therapeutics, Inc. BiotechnologyHealth Technology Versatope Therapeutics, Inc. is an immuno-therapeutic company based in Lowell, MA. The private company harnesses a customized biotechnology platform to deliver immunity using state-of-the-art synthetic biology and bioinformatics. The company customizes exosome-like vesicles made from probiotics to display targets in a 3D context that activates potent immunity. The company's lead vaccine candidate addresses the need for improved, effective universal influenza vaccines to prevent influenza and other emerging infectious diseases, such as the current COVID-19. The company was founded in 2017 by Christopher Locher and Dave Putnam, and Christopher Locher has been the CEO since 2017. | - |
Sara Cotter | F | 43 | 1 anni | |
Volker Gerdts | M | - |
Vaccine & Infectious Disease Organization
| - |
Baljit Singh | M | - |
Vaccine & Infectious Disease Organization
| - |
Gerald Parker | M | - |
Vaccine & Infectious Disease Organization
| - |
Gillian Muir | M | - |
Vaccine & Infectious Disease Organization
| - |
Tippi Mak | M | - |
Vaccine & Infectious Disease Organization
| - |
Kari Harvey | F | - |
Vaccine & Infectious Disease Organization
| - |
Ryan Thompson | M | - |
Vaccine & Infectious Disease Organization
| - |
Robert Allen | M | 55 | 1 anni | |
Jim Kuo | M | - |
Versatope Therapeutics, Inc.
![]() Versatope Therapeutics, Inc. BiotechnologyHealth Technology Versatope Therapeutics, Inc. is an immuno-therapeutic company based in Lowell, MA. The private company harnesses a customized biotechnology platform to deliver immunity using state-of-the-art synthetic biology and bioinformatics. The company customizes exosome-like vesicles made from probiotics to display targets in a 3D context that activates potent immunity. The company's lead vaccine candidate addresses the need for improved, effective universal influenza vaccines to prevent influenza and other emerging infectious diseases, such as the current COVID-19. The company was founded in 2017 by Christopher Locher and Dave Putnam, and Christopher Locher has been the CEO since 2017. | 3 anni |
Matt DeLisa | M | - |
Versatope Therapeutics, Inc.
![]() Versatope Therapeutics, Inc. BiotechnologyHealth Technology Versatope Therapeutics, Inc. is an immuno-therapeutic company based in Lowell, MA. The private company harnesses a customized biotechnology platform to deliver immunity using state-of-the-art synthetic biology and bioinformatics. The company customizes exosome-like vesicles made from probiotics to display targets in a 3D context that activates potent immunity. The company's lead vaccine candidate addresses the need for improved, effective universal influenza vaccines to prevent influenza and other emerging infectious diseases, such as the current COVID-19. The company was founded in 2017 by Christopher Locher and Dave Putnam, and Christopher Locher has been the CEO since 2017. | - |
Francisco Diaz-Mitoma | M | 69 |
Vaccine & Infectious Disease Organization
| 2 anni |
Stacy Price | F | 55 | 1 anni | |
Salim Yazji | M | 55 |
Versatope Therapeutics, Inc.
![]() Versatope Therapeutics, Inc. BiotechnologyHealth Technology Versatope Therapeutics, Inc. is an immuno-therapeutic company based in Lowell, MA. The private company harnesses a customized biotechnology platform to deliver immunity using state-of-the-art synthetic biology and bioinformatics. The company customizes exosome-like vesicles made from probiotics to display targets in a 3D context that activates potent immunity. The company's lead vaccine candidate addresses the need for improved, effective universal influenza vaccines to prevent influenza and other emerging infectious diseases, such as the current COVID-19. The company was founded in 2017 by Christopher Locher and Dave Putnam, and Christopher Locher has been the CEO since 2017. | 5 anni |
Amy Cronin | F | - |
Vaccine & Infectious Disease Organization
| - |
Dieter Schillinger | M | - |
Vaccine & Infectious Disease Organization
| - |
Cornelia Kreplin | M | - |
Vaccine & Infectious Disease Organization
| - |
Jonathan Klock | M | - |
Emergent Travel Health, Inc.
![]() Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | 10 anni |
Brenda McCabe | F | - |
Versatope Therapeutics, Inc.
![]() Versatope Therapeutics, Inc. BiotechnologyHealth Technology Versatope Therapeutics, Inc. is an immuno-therapeutic company based in Lowell, MA. The private company harnesses a customized biotechnology platform to deliver immunity using state-of-the-art synthetic biology and bioinformatics. The company customizes exosome-like vesicles made from probiotics to display targets in a 3D context that activates potent immunity. The company's lead vaccine candidate addresses the need for improved, effective universal influenza vaccines to prevent influenza and other emerging infectious diseases, such as the current COVID-19. The company was founded in 2017 by Christopher Locher and Dave Putnam, and Christopher Locher has been the CEO since 2017. | 5 anni |
Rory A. McAlpine | M | - |
Vaccine & Infectious Disease Organization
| - |
Preston Smith | M | - |
Vaccine & Infectious Disease Organization
| - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
David Hering | M | 49 | 3 anni | |
Fred Driscoll | M | 73 | 1 anni | |
Michael Wyzga | M | 69 | 3 anni | |
Peter Schmidt | M | - | - | |
Laura Walker | M | 40 | 3 anni | |
Kyra Faircloth | F | - | - | |
Rich Tong | M | - |
Emergent Travel Health, Inc.
![]() Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | 7 anni |
Jim Connolly | M | 59 |
Emergent Travel Health, Inc.
![]() Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | 4 anni |
Rebecca Dabora | M | 66 | 3 anni | |
Clive Meanwell | M | 67 | 2 anni | |
Mark Meltz | M | 50 |
Emergent Travel Health, Inc.
![]() Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | 5 anni |
Kurt Reichen | M | - |
Emergent Travel Health, Inc.
![]() Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | 4 anni |
Lisa Danzig | M | - |
Emergent Travel Health, Inc.
![]() Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | 3 anni |
Martin Dearden | M | - |
Emergent Travel Health, Inc.
![]() Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | 5 anni |
Kevin Smyth | M | - |
Emergent Travel Health, Inc.
![]() Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | 4 anni |
Linda Rubinstein | F | 58 |
Emergent Travel Health, Inc.
![]() Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | - |
Howard Rosen | M | 66 |
Emergent Travel Health, Inc.
![]() Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | 8 anni |
Dean Mitchell | M | 68 |
Emergent Travel Health, Inc.
![]() Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | 2 anni |
Sandra Pennell | F | - | 2 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 30 | 69.77% |
Canada | 13 | 30.23% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Jeremy Gowler
- Contatti personali